Vascular endothelial growth factor (VEGF) is a key molecule that orchestrates the formation and function of vascular networks. Impaired regulation of angiogenesis is implicated in a number of pathologic states. For instance, neoplasias exhibit uncontrolled angiogenesis, whereas ischemia and states of vascular insufficiency involve reduced VEGF activity. As the role of VEGF has been elucidated in these disease processes, its therapeutic role has been developed. The Food and Drug Administration has approved several anti-VEGF agents for treating colorectal, lung, and kidney cancer. VEGF-inducing agents have also been used experimentally to induce angiogenesis in patients with critical limb ischemia. As more knowledge is gathered about the biology of VEGF and its receptors, there is greater promise for therapeutic modulation of VEGF expression. The purpose of this review is to describe the various therapeutic and biologic factors that regulate the expression of VEGF.
Baldwin ME, Stacker SA, Achen MGMolecular control of lymphangiogenesis. Bioessays . 2002;24:1030-1040.
2.
Nagy JA, Vasile E., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med . 2002;196:1497-1506.
3.
Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101: 4878-4886.
4.
Ohm JE, Carbone DPVEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23:263-272.
5.
Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201.
6.
Rafii S., Lyden D., Benezra R., Hattori K., Heissig B.Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002;2:826-835.
7.
Mann DR, Plant TMLeptin and pubertal development. Semin Reprod Med . 2002;20:93-102.
8.
Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003 ;107:1359-1365.
9.
Loureiro RM, D'Amore PATranscriptional regulation of vascular endothelial growth factor in cancer . Cytokine Growth Factor Rev. 2005;16:77-89.
10.
Cardones AR , Banez LLVEGF inhibitors in cancer therapy . Curr Pharm Des. 2006;12:387-394.
Willett CG, Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
13.
Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
14.
Giantonio BJ , Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
15.
Sund M., Zeisberg M., Kalluri R.Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application. Gastroenterology . 2005;129:2076-2091.
16.
Yang JC, Haworth L., Sherry RM, et al. Bevacizumab in renal cell carcinoma. N Engl J Med. 2003;349:427-434.
17.
Johnson DH, Fehrenbacher L., Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191.
18.
Han ES, Monk BJBevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther. 2007;7:1339-1345.
19.
Goldman JM, Melo JVTargeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084-1086.
20.
Motzer RJ, Hutson TE, Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma . N Engl J Med. 2007;356:115-124.
21.
Huang J., Frischer JS, Serur A., et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003;100:7785-7790.
22.
Merrill MJ, Oldfield EHA reassessment of vascular endothelial growth factor in central nervous system pathology. J Neurosurg. 2005;103:853-868.
23.
Ilzecka J.Does VEGF represent a potential treatment for amyotrophic lateral sclerosis ? Curr Opin Investig Drugs. 2006 ;7:54-59.
24.
Podar K., Anderson KCThe pathopysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383-1395.
25.
Almand B., Resser JR, Lindman B., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755-1766.
26.
Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996 ;2:1096-1103.
27.
Gabrilovich DI, Ishida T., Nadaf S., Ohm JE, Carbone DPAntibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963-2970.
28.
Kaga S., Zhan L., Matsumoto M., Maulik N.Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol. 2005;39:813-822.
29.
Garvin S., Ollinger K., Dabrosin C.Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006 ;231:113-122.
30.
Park JS, Qiao L., Su ZZ, et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene. 2001;20:3266-3280.
31.
Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374-3378.
32.
Brieger J., Kattwinkel J., Berres M., Gosepath J., Mann WJImpact of vascular endothelial growth factor release on radiation resistance . Oncol Rep. 2007;18:1597-1601.
33.
Willett CG, Kozin SV, Duda DG, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol. 2006;33(4, suppl 10):S35-S40.
34.
Kastrup J., Jorgensen E., Ruck A., et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol.2005;45:982-988.
35.
Couffinhal T. , Kearney M., Witzenbichler B., et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries . Am J Pathol. 1997;150:1673-1685.
36.
Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998;98:2108-2116.
37.
Brasen JH, Kivela A., Roser K., et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arterioscler Thromb Vasc Biol. 2001;21:1720-1726.
38.
Rutanen J., Leppanen P., Tuomisto TT, et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res. 2003;59:971-979.
39.
Laitinen M. , Zachary I., Breier G., et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 1997;8:1737-1744.
40.
Laitinen M. , Hartikainen J., Hiltunen MO, et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther. 2000;11:263-270.
41.
Hedman M., Hartikainen J., Syvanne M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003;107:2677-2683.
42.
Rajagopalan S., Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003 ;108:1933-1938.
43.
Howell WM, Ali S., Rose-Zerilli MJ, Ye S.VEGF polymorphisms and severity of atherosclerosis. J Med Genet. 2005;42:485-490.
44.
Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123.
45.
Yu J., Lei L., Liang Y., et al. An engineered VEGFactivating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. FASEB J. 2006;20:479-481.
46.
Deiner C., Schwimmbeck PL, Koehler IS, et al. Adventitial VEGF165 gene transfer prevents lumen loss through induction of positive arterial remodeling after PTCA in porcine coronary arteries . Atherosclerosis. 2006;189:123-132.
47.
Hendel RC, Henry TD, Rocha-Singh K., et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect . Circulation. 2000;101:118-121.
48.
Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia. Circulation. 1998;98:2800-2804.
49.
Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation. 2000;102:965-974.
50.
Sylven C., Sarkar N., Ruck A., et al. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris . Coron Artery Dis. 2001;12:239-243.
51.
Reilly JP, Grise MA, Fortuin FD, et al. Long-term (2-year) clinical events following transthoracic intra-myocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol . 2005;18:27-31.
52.
Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind,dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation . 2002;105:2012-2018.
53.
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HFTumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
Keck PJ, Hauser SD, Krivi G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
56.
Mattei MG, Borg JP, Rosnet O., Marme D., Birnbaum D.Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively . Genomics. 1996;32:168-169.
57.
Paavonen K. , Horelli-Kuitunen N., Chilov D., et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation. 1996;93:1079-1082.
58.
Joukov V., Pajusola K., Kaipainen A., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298.
59.
Yamada Y., Nezu J., Shimane M., Hirata Y.Molecular cloning of a novel vascular endothelial growth factor, VEGF-D . Genomics. 1997;42:483-488.
60.
Lyttle DJ, Fraser KM, Fleming SB, Mercer AA, Robinson AJHomologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol. 1994;68:84-92.
61.
Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., Persico MGIsolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A . 1991;88:9267-9271.
62.
Olofsson B. , Korpelainen E., Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95:11709-11714.
63.
Makinen T., Olofsson B., Karpanen T., et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem . 1999;274:21217-21222.
64.
Achen MG, Jeltsch M., Kukk E., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548-553.
65.
Stacker SA, Stenvers K., Caesar C., et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem. 1999;274:32127-32136.
66.
Wise LM, Veikkola T., Mercer AA, et al. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci U S A. 1999;96:3071-3076.
Zachary I., Gliki G.Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568-581.
69.
Matsumoto T. , Claesson-Welsh L.VEGF receptor signal transduction . Sci STKE.2001;2001:RE21.
70.
Cross MJ, Claesson-Welsh L.FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci . 2001;22:201-207.
71.
Cao Y., Ji WR, Qi P., Rosin A., Cao Y.Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun. 1997;235:493-498.
72.
Park JE, Chen HH, Winer J., Houck KA, Ferrara N.Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem.1994;269:25646-25654.
73.
Shweiki D., Itin A., Soffer D., Keshet E.Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992 ;359:843-845.
74.
Soker S., Takashima S., Miao HQ, Neufeld G., Klagsbrun M.Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735-745.
75.
Stacker SA, Baldwin ME, Achen MGThe role of tumor lymphangiogenesis in metastatic spread. FASEB J. 2002;16:922-934.
76.
Karkkainen MJ, Saaristo A., et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A. 2001;98:12677-12682.
77.
Ferrara N., Henzel WJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun . 1989;161:851-858.
78.
DiSalvo J., Bayne ML, Conn G., et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J Biol Chem.1995;270:7717-7723.
79.
Xie K., Wei D., Shi D., Huang S.Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 2004;15:297-324.
80.
Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett. 2006;103:159-166.
81.
Kaushansky K., Kirito K.Thombopoietin stimulates vascular endothelial cell growth factor (VEGF) production in hematopoietic stem cells . Cell Cycle. 2005;3:1729-1731.
82.
Minchenko A. , Bauer T., Salceda S., Caro J.Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest . 1994;71:374-379.
83.
Shima DT, Adamis AP, Ferrara N., et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995 ;1:182-193.
84.
Brooks SE, Gu X., Kaufmann PM, Marcus DM, Caldwell RBModulation of VEGF production by pH and glucose in retinal Muller cells. Curr Eye Res. 1998;17:875-882.
85.
D'Arcangelo D., Facchiano F., Barlucchi LM, et al. Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression. Circ Res. 2000;86:312-318.
86.
Scott PA, Gleadle JM, Bicknell R., Harris ALRole of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int J Cancer. 1998;75:706-712.
87.
Damert A., Ikeda E., Risau W.Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J. 1997;327(pt 2):419-423.
88.
Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem.1991;266:11947-11954.
89.
Gray MJ, Zhang J., Ellis LM, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005;24:3110-3120.
90.
Shi Q., Le X., Abbruzzese JL, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma . Cancer Res. 2001;61:4143-4154.
91.
Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., Marme D.Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel Lindau tumor suppressor protein. Cancer Res. 1996 ;56:2299-2301.
92.
Cohen HT, Zhou M., Welsh AM, et al. An important von Hippel Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun . 1999;266:43-50.
93.
Zhang L., Yu D., Hu M., et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 2000 ;60:3655-3661.
94.
Pal S., Datta K., Mukhopadhyay D.Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 2001;61:6952-6957.
95.
Salimath B. , Marme D., Finkenzeller G.Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene . 2000;19:3470-3476.
96.
Mukhopadhyay D., Tsiokas L., Zhou XM, Foster D., Brugge JS, Sukhatme VPHypoxic induction of human vascular endothelial growth factor expression through c-Src activation . Nature . 1995;375:577-581.
97.
Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., Kerbel RSOncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 1995;14:263-277.
98.
Ryuto M., Ono M., Izumi H., et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem.1996;271:28220-28228.
99.
Schafer G., Cramer T., Suske G., Kemmner W., Wiedenmann B., Hocker M.Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem. 2003;278:8190-8198.
100.
Berra E., Milanini J., Richard DE, et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol. 2000;60:1171-1178.
101.
Kimura H., Weisz A., Kurashima Y., et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood . 2000;95:189-197.
102.
Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., Ilan N.Heparanase induces vascular endothelial growth factor expression: Correlation with p38 phophorylation levels and Src activation. Cancer Res. 2006;66:1455-1463.
103.
Wei D. , Le X., Zheng L., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22:319-329.
104.
Wei LH , Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22:1517-1527.
105.
Niu G. , Wright KL, Huang M., et al. Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene . 2002;21:2000-2008.
106.
Loeffler S. , Fayard B., Weis J., Weissenberger J.Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in gliobastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer. 2005;115:202-213.
107.
Swannie HC , Kaye SBProtein kinase C inhibitors. Curr Oncol Rep. 2002;4:37-46.
108.
Nishizuka Y.Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607-614.
109.
Michiels C. , Minet E., Michel G., Mottet D., Piret JP, Raes M.HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life. 2001;52:49-53.
110.
Minet E., Michel G., Mottet D., et al. c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res. 2001;265:114-124.
111.
Karin M., Liu Z., Zandi E.AP-1 function and regulation. Curr Opin Cell Biol . 1997;9:240-246.
112.
Karin M., Shaulian E.AP-1: linking hydrogen peroxide and oxidative stress to the control of cell proliferation and death. IUBMB Life. 2001;52:17-24.
113.
Brenneisen P. , Blaudschun R., Gille J., et al. Essential role of an activator protein-2 (AP-2)/specificity protein 1 (Sp1) cluster in the UVB-mediated induction of the human vascular endothelial growth factor in HaCaT keratinocytes. Biochem J. 2003;369(pt 2):341-349.
114.
Schwarte-Waldhoff I., Schmiegel W.Smad4 transcriptional pathways and angiogenesis . Int J Gastrointest Cancer. 2002;31:47-59.
115.
Schwarte-Waldhoff I., Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A. 2000;97:9624-9629.
116.
Levy AP, Levy NS, Goldberg MAPost-transcriptional regulation of vascular endothelial growth factor by hypoxia . J Biol Chem. 1996;271:2746-2753.
117.
Koyanagi S. , Kuramoto Y., Nakagawa H., et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003;63:7277-7283.
118.
Levy NS, Chung S., Furneaux H., Levy APHypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem. 1998;273:6417-6423.
119.
Pages G., Berra E., Milanini J., Levy AP, Pouyssegur J.Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem. 2000;275:26484-26491.
120.
Stein I., Itin A., Einat P., Skaliter R., Grossman Z., Keshet E.Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol. 1998;18:3112-3119.
121.
Huez I., Creancier L., Audigier S., Gensac MC, Prats AC, Prats H.Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol. 1998;18:6178-6190.
122.
Kevil CG, De Benedetti A., Payne DK, Coe LL, Laroux FS, Alexander JSTranslational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer . 1996;65:785-790.
123.
Li BD, Liu L., Dawson M., De Benedetti A.Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma . Cancer. 1997;79:2385-2390.
124.
Crew JP, Fuggle S., Bicknell R., Cranston DW, de Benedetti A., Harris ALEukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer. 2000;82:161-166.
125.
Kuwabara K. , Matsumoto M., Ikeda J., et al. Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. J Biol Chem. 1996;271:5025-5032.
126.
Ozawa K., Kondo T., Hori O., et al. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J Clin Invest. 2001;108:41-50.
127.
Igarashi H. , Esumi M., Ishida H., Okada K.Vascular endothelial growth factor overexpression is correlated with von Hippel Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer. 2002;95:47-53.
128.
Rak J. , Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis . Cancer Res. 1995;55:4575-4580.
129.
Larcher F. , Robles AI, Duran H., et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res. 1996 ;56:5391-5396.
130.
D'Arcangelo G., Habas R., Wang S., Halegoua S., Salton SRActivation of codependent transcription factors is required for transcriptional induction of the vgf gene by nerve growth factor and Ras. Mol Cell Biol . 1996;16:4621-4631.
131.
White FC, Benehacene A., Scheele JS, Kamps M.VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation evidence for divergent stabilization pathways. Growth Factors. 1997;14:199-212.
132.
Milanini-Mongiat J., Pouyssegur J., Pages G.Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem. 2002;277:206-231.
133.
Hoshino R. , Chatani Y., Yamori T., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813-822.
134.
Schmidt CM , McKillop IH, Cahill PA, Sitzmann JVIncreased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun. 1997;236:54-58.
135.
Govindarajan B., Bai X., Cohen C., et al. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase (MAPK) signaling. J Biol Chem. 2003;278:9790-9795.
136.
Katsanakis KD, Owen C., Zoumpourlis V.JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role . Anticancer Res. 2002;22:755-759.
137.
Richard DE, Berra E., Gothie E., Roux D., Pouyssegur J.p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1 . J Biol Chem. 1999;274:32631-32637.
138.
Okajima E., Thorgeirsson UPDifferent regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem Biophys Res Commun. 2000;270:108-111.
139.
Miao H., Wei BR, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol. 2001;3:527-530.
140.
Zhang X., Gaspard JP, Chung DCRegulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001;61:6050-6054.
141.
Fleming RY , Ellis LM, Parikh NU, Liu W., Staley CA, Gallick GERegulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase . Surgery. 1997;122:501-507.
142.
Yen L. , Benlimame N., Nie ZR, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell. 2002;13:4029-4044.
143.
Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo MLUp-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem.2003;278:5750-5759.
144.
Mayerhofer M., Valent P., Sperr WR, Griffin JD, Sillaber C.BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002;100:3767-3775.
145.
Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., Kerbel RSOncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 2000;19:4611-4620.
146.
Mukhopadhyay D., Knebelmann B., Cohen HT, Ananth S., Sukhatme VPThe von Hippel Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol . 1997;17:5629-5639.
147.
Kawai H., Li H., Chun P., Avraham S., Avraham HKDirect interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 2002;21:7730-7739.
148.
Cianchi F. , Cortesini C., Fantappie O., et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol. 2003;162:793-801.
149.
Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998;90:587-596. 150. Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect. 2000;108:785-790.
150.
Goldhar AS , Vonderhaar BK, Trott JF, Hovey RCProlactin-induced expression of vascular endothelial growth factor via Egr-1. Mol Cell Endocrinol. 2005;232:9-19.
151.
Cherradi N. , Lejczak C., Desroches-Castan A., Feige JJAntagonistic functions of Tis11b and HuR in the hormonal regulation of vascular endothelial growth factor mRNA stability by adrenocorticotropin. Mol Endocrinol . 2005;20:916-930.
152.
Cheng SY, Hu B., Bar-Joseph I., Hu B., Cheng SYEstradiol and nicotine exposure enhances A549 bronchioalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol. 2006;28:337-344.
153.
Chua CC, Hamdy RC, Chua BHUpregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biphys Acta. 1998;1401:187-194.
154.
Gille J., Reisinger K., Asbe-Vollkopf A., Hardt-Weinelt K., Kaufmann R.Ultraviolet-A-induced transactivation of the vascular endothelial growth factor gene in HaCaT keratinocytes is conveyed by activator protein-2 transcription factor. J Invest Dermatol. 2000 ;115:30-36.
155.
Chen JT, Liang JB, Chou CL, Shyu RC, Lu DWRetinoic acid induces VEGF gene expression in human retinal pigment epithelial cells (ARPE-19). J Ocul Pharmacol Ther. 2005 ;21:413-419.
156.
Bamba H., Ota S., Kato A., Kawamoto C., Fujiwara K.Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways indifferentiated U937 cells. Biochem Biophys Res Commun. 2000;273:485-491.
157.
Funamoto M. , Fujio Y., Kunisada K., et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem . 2000;275:10561-10566.
158.
Pufe T., Kurz B., Petersen W., et al. The influence of biomechanical parameters on the expression of VEGF and endostatin in the bone and joint system. Ann Anat . 2005;187:461-472.
159.
Hiltunen MO , Laitinen M., Turunen MP, et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation. 2000;102:2262-2268.
